JP Morgan keeps Neutral ratings on Fabrinet and Halozyme and lifts price targets slightly
JP Morgan kept Neutral ratings on Fabrinet and Halozyme Therapeutics and raised price targets to $470 and $79. The data was published by TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
JP Morgan analysts kept their Neutral rating on Fabrinet shares and raised the price target from $465 to $470, an increase of 1.1%. That target implies a 49.3% gain from the November 2 closing price of $314.70. The information comes from TradingView, which cites data provided by Benzinga.
The bank also kept a Neutral rating on Halozyme Therapeutics and moved its target from $78 to $79, a rise of 1.3%. That level implies a 38.7% decline from the November 2 close of $128.95. Both updates were published on November 3.
why it matters
Revisions like these are part of routine analyst coverage. Small changes to price targets rarely move the market, so investors usually focus more on the overall tone of ratings and the companies' own results. Differing views across banks also show that opinions on both stocks remain mixed.
tags
instruments
sources
- JP Morgan maintains Fabrinet at Neutral, raises price target to $470 from $465 — TradingView, 3 November 2026 at 17:45 UTC
- JP Morgan maintains Halozyme Therapeutics at Neutral, raises price target to $79 from $78 — TradingView, 3 November 2026 at 17:55 UTC
- JP Morgan maintains Inspire Medical Systems at Neutral, raises price target to $65 from $60 — TradingView, 3 November 2026 at 18:00 UTC
- JP Morgan maintains Huntington Ingalls Indus at Neutral, raises price target to $375 from $370 — TradingView, 3 November 2026 at 17:57 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗